Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 1:00–2:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic
breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Jan. 6, 2021—Optum, a part of UnitedHealth Group, and Change Healthcare have agreed to combine. Change Healthcare will join with the OptumInsight business to provide software and data analytics, technology-enabled services and research, and advisory and revenue cycle management offerings.
Dec. 29, 2020—Quidel received emergency use authorization from the FDA to market its Solana SARS-CoV-2 assay
Dec. 28, 2020—CompuGroup Medical has acquired eMDs, a provider of ambulatory information systems and outsourcing services for medical accounting, for approximately $240 million.
Dec. 23, 2020—AstraZeneca’s Tagrisso (osimertinib) has been FDA approved for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after tumor resection with curative intent.
Dec. 22, 2020 —Quidel announced it received emergency use authorization from the FDA to market its QuickVue SARS Antigen test, a point-of-care assay for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in anterior nares swab specimens from people who are suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms.
Dec. 21, 2020—Randox announced that its improved software for the Vivalytic analysis device enables its CE-marked Vivalytic SARS-CoV-2 rapid coronavirus test to deliver results for positive samples in less than 30 minutes.
Dec. 18, 2020—Beckman Coulter launched the Access SARS-CoV-2 Antigen assay, a high-throughput COVID-19 test available in the U.S., priced at $4 to health care providers, including public and private institutions, governments, and nonprofits.
Dec. 16, 2020—The FDA issued an emergency use authorization for the first over-the-counter, at-home diagnostic test for COVID-19.
Dec. 15, 2020—Roche launched the Cobas PIK3CA Mutation Test CE-IVD for patients with advanced or metastatic breast cancer in countries accepting the CE mark.
Dec. 11, 2020—Siemens Healthineers announced it received the CE mark and FDA 510(k) clearance for the Epoc NXS Host mobile computer
